Prostaglandins F
(9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics.
Networked: 673
relevant articles (24 outcomes,
72 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
- Lipids: 114793
- Fatty Acids: 27405
- Unsaturated Fatty Acids: 8236
- Eicosanoids: 3262
- Prostaglandins: 17100
- Prostaglandins F: 673
- Dinoprost: 1562
- 6-Ketoprostaglandin F1 alpha: 550
- prostaglandin F1: 239
- tafluprost: 155
- alfaprostol: 6
- Ecraprost: 5
- prostaglandin F-main urinary metabolite: 4
- 3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy -1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoic acid (5Z)-7-((1R,2R: 3
- prostaglandin F2beta: 1
- prostaglandin F3alpha: 1
- 1,2,3,4-tetranortafluprost acid
- 1,2-dinortafluprost acid
- 15-cis-(4-n-propylcyclohexyl)-16,17,17,19,20-pentanor-9-deoxy-6,9-alpha-nitriloprostaglandin F1
- 2,3-dinor-6-oxoprostaglandin F1beta
- 5(6)-epoxyprostaglandin F1 alpha
- 5,6-dihydroxyprostaglandin F1
- 5,7-dihydroxy-11-ketotetranorprostanoic acid
- C22-prostaglandin F4alpha
- lymphocytic thyroid stimulator (non-immunoglobulin)
- prostaglandin F1beta
- Biological Factors: 2472
- Inflammation Mediators: 1113
- Autacoids: 276
- Eicosanoids: 3262
- Prostaglandins: 17100
- Prostaglandins F: 673
- Dinoprost: 1562
- 6-Ketoprostaglandin F1 alpha: 550
- prostaglandin F1: 239
- tafluprost: 155
- alfaprostol: 6
- Ecraprost: 5
- prostaglandin F-main urinary metabolite: 4
- 3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy -1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoic acid (5Z)-7-((1R,2R: 3
- prostaglandin F2beta: 1
- prostaglandin F3alpha: 1
- 1,2,3,4-tetranortafluprost acid
- 1,2-dinortafluprost acid
- 15-cis-(4-n-propylcyclohexyl)-16,17,17,19,20-pentanor-9-deoxy-6,9-alpha-nitriloprostaglandin F1
- 2,3-dinor-6-oxoprostaglandin F1beta
- 5(6)-epoxyprostaglandin F1 alpha
- 5,6-dihydroxyprostaglandin F1
- 5,7-dihydroxy-11-ketotetranorprostanoic acid
- C22-prostaglandin F4alpha
- lymphocytic thyroid stimulator (non-immunoglobulin)
- prostaglandin F1beta
Experts
1. | Basu, Samar:
12 articles
(01/2015 - 10/2002)
|
2. | Carmeliet, Peter:
7 articles
(01/2019 - 11/2010)
|
3. | Jabbour, Henry N:
7 articles
(08/2011 - 02/2004)
|
4. | Wang, Yu:
6 articles
(01/2022 - 06/2004)
|
5. | Li, Yuhao:
6 articles
(01/2012 - 06/2005)
|
6. | Yamahara, Johji:
6 articles
(01/2012 - 06/2005)
|
7. | Huang, Xiao-Jun:
5 articles
(01/2022 - 10/2015)
|
8. | Kong, Yuan:
5 articles
(01/2022 - 01/2018)
|
9. | Xu, Lan-Ping:
5 articles
(01/2022 - 10/2015)
|
10. | Zhang, Xiao-Hui:
5 articles
(01/2022 - 10/2015)
|
Related Diseases
1. | Endometritis
|
2. | Wounds and Injuries (Trauma)
|
3. | Diabetic Nephropathies (Diabetic Nephropathy)
|
4. | Anemia
12/01/2015
- " In 20 adult patients with poor graft function (PGF defined as transfusion-dependent platelet counts <20,000/µl, or leukocytes <1500/µl, or transfusion-dependent anemia) and variable causes of PGF after allogeneic PBSCT, immunomagnetically selected CD34(+) stem cell boosts (SCB) from matched unrelated (n = 8), mismatched unrelated (n = 11) or haploidentical (n = 1) donors were applied without prior conditioning. " 01/01/2021
- " Severe GVHD, thrombocytopenia and anemia portended inferior survival and were used to develop a prognostic score for mortality from PGF. " 01/01/2018
- " Eltrombopag, an oral thrombopoietin receptor agonist, which showed promising results in severe aplasia anemia, may be an alternative choice for PGF patients. " 08/01/2008
- " From PTCF, glycoprotein-enriched fraction (PGF, >90% protein, approximately 15 kDa determined by SDS-PAGE) was separated as active ingredient that ameliorates 5-FU-induced anemia. "
|
5. | Inflammation (Inflammations)
|
|
Related Drugs and Biologics
Related Therapies and Procedures